The global hemophilia drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of hemophilia and growing awareness about the disease. Hemophilia A and B are the two most common types of hemophilia, which account for more than 90% of all cases globally. Hemophilia A is caused by a deficiency in clotting factor VIII, while Hemophilia B is caused by a deficiency in clotting factor IX. Inhibitors are also one of the major types of hemophilias that can cause bleeding disorders due to their ability to inhibit coagulation factors such as Factor VIII or Factor IX. Recombinant therapies are used for treating patients with severe forms of hemophilias who have developed inhibitors against clotting factors VIII or IX, whereas plasm-derived therapies are used for treating patients with milder forms who do not have inhibitors against these clotting factors but require regular infusions due to low levels in their blood plasma.
North America accounted for the largest share in terms of revenue generated from sales across all regions during 2018 and this trend is expected to continue over the forecast period owing to high prevalence rates among people living there and increased awareness about treatment options available for people suffering from this condition. Europe followed North America closely with its share accounting for around 25% revenue generated from sales across all regions during 2018; however, it will witness an increase in its share over time owing to increasing number cases being diagnosed every year coupled with higher spending on healthcare services per capita compared with other regions such as Asia Pacific and Middle East & Africa.
- The global Hemophilia Drugs market is expected to grow at a CAGR of 5.5% from 2017 to 2022.
- The increasing prevalence of hemophilia and the growing number of patients with hemophilia are the major factors driving the growth of this market.
- Increasing awareness about hemophilia and its treatment options is also expected to fuel the growth of this market in coming years.
- The high cost associated with these drugs is one factor that may hamper the growth of this market in coming years as it may lead to reduced patient access and increased healthcare expenditure for patients suffering from hemophilia globally.
Industry Growth Insights published a new data on “Hemophilia Drugs Market”. The research report is titled “Hemophilia Drugs Market research by Types (Hemophilia A, Inhibitors, Hemophilia B, Von Willebrand Disease), By Applications (Recombinant Therapies, Plasma-Derived Therapies), By Players/Companies Baxalta, Bayer, CSL Behring, Pfizer, Alnylam Pharmaceuticals, BioMarin, Catalyst Biosciences, Dimension Therapeutics, F. Hoffmann-La Roche, Grifols, Octapharma, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemophilia Drugs Market Research Report
By Type
Hemophilia A, Inhibitors, Hemophilia B, Von Willebrand Disease
By Application
Recombinant Therapies, Plasma-Derived Therapies
By Companies
Baxalta, Bayer, CSL Behring, Pfizer, Alnylam Pharmaceuticals, BioMarin, Catalyst Biosciences, Dimension Therapeutics, F. Hoffmann-La Roche, Grifols, Octapharma, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Hemophilia Drugs Market Report Segments:
The global Hemophilia Drugs market is segmented on the basis of:
Types
Hemophilia A, Inhibitors, Hemophilia B, Von Willebrand Disease
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Recombinant Therapies, Plasma-Derived Therapies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxalta
- Bayer
- CSL Behring
- Pfizer
- Alnylam Pharmaceuticals
- BioMarin
- Catalyst Biosciences
- Dimension Therapeutics
- F. Hoffmann-La Roche
- Grifols
- Octapharma
- Sangamo Biosciences
- Spark Therapeutics
- Swedish Orphan Biovitrum
Highlights of The Hemophilia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hemophilia A
- Inhibitors
- Hemophilia B
- Von Willebrand Disease
- By Application:
- Recombinant Therapies
- Plasma-Derived Therapies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemophilia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemophilia drugs are medications used to help control bleeding episodes in people with hemophilia. These drugs work by helping to prevent or reduce the amount of blood that is lost during an episode. Hemophilia drugs can also help improve the quality of life for people with hemophilia by reducing pain and improving mobility.
Some of the key players operating in the hemophilia drugs market are Baxalta, Bayer, CSL Behring, Pfizer, Alnylam Pharmaceuticals, BioMarin, Catalyst Biosciences, Dimension Therapeutics, F. Hoffmann-La Roche, Grifols, Octapharma, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum.
The hemophilia drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hemophilia Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hemophilia Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hemophilia Drugs Market - Supply Chain
4.5. Global Hemophilia Drugs Market Forecast
4.5.1. Hemophilia Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hemophilia Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hemophilia Drugs Market Absolute $ Opportunity
5. Global Hemophilia Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hemophilia Drugs Market Size and Volume Forecast by Type
5.3.1. Hemophilia A
5.3.2. Inhibitors
5.3.3. Hemophilia B
5.3.4. Von Willebrand Disease
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hemophilia Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hemophilia Drugs Market Size and Volume Forecast by Application
6.3.1. Recombinant Therapies
6.3.2. Plasma-Derived Therapies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hemophilia Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hemophilia Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hemophilia Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hemophilia Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hemophilia Drugs Demand Share Forecast, 2019-2026
9. North America Hemophilia Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hemophilia Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hemophilia Drugs Market Size and Volume Forecast by Application
9.4.1. Recombinant Therapies
9.4.2. Plasma-Derived Therapies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hemophilia Drugs Market Size and Volume Forecast by Type
9.7.1. Hemophilia A
9.7.2. Inhibitors
9.7.3. Hemophilia B
9.7.4. Von Willebrand Disease
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hemophilia Drugs Demand Share Forecast, 2019-2026
10. Latin America Hemophilia Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hemophilia Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hemophilia Drugs Market Size and Volume Forecast by Application
10.4.1. Recombinant Therapies
10.4.2. Plasma-Derived Therapies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hemophilia Drugs Market Size and Volume Forecast by Type
10.7.1. Hemophilia A
10.7.2. Inhibitors
10.7.3. Hemophilia B
10.7.4. Von Willebrand Disease
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hemophilia Drugs Demand Share Forecast, 2019-2026
11. Europe Hemophilia Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hemophilia Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hemophilia Drugs Market Size and Volume Forecast by Application
11.4.1. Recombinant Therapies
11.4.2. Plasma-Derived Therapies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hemophilia Drugs Market Size and Volume Forecast by Type
11.7.1. Hemophilia A
11.7.2. Inhibitors
11.7.3. Hemophilia B
11.7.4. Von Willebrand Disease
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hemophilia Drugs Demand Share, 2019-2026
12. Asia Pacific Hemophilia Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hemophilia Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hemophilia Drugs Market Size and Volume Forecast by Application
12.4.1. Recombinant Therapies
12.4.2. Plasma-Derived Therapies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hemophilia Drugs Market Size and Volume Forecast by Type
12.7.1. Hemophilia A
12.7.2. Inhibitors
12.7.3. Hemophilia B
12.7.4. Von Willebrand Disease
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hemophilia Drugs Demand Share, 2019-2026
13. Middle East & Africa Hemophilia Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hemophilia Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hemophilia Drugs Market Size and Volume Forecast by Application
13.4.1. Recombinant Therapies
13.4.2. Plasma-Derived Therapies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hemophilia Drugs Market Size and Volume Forecast by Type
13.7.1. Hemophilia A
13.7.2. Inhibitors
13.7.3. Hemophilia B
13.7.4. Von Willebrand Disease
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hemophilia Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hemophilia Drugs Market: Market Share Analysis
14.2. Hemophilia Drugs Distributors and Customers
14.3. Hemophilia Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Baxalta
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CSL Behring
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Alnylam Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BioMarin
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Catalyst Biosciences
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Dimension Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. F. Hoffmann-La Roche
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Grifols
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Octapharma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sangamo Biosciences
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Spark Therapeutics
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Swedish Orphan Biovitrum
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
